Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02544490
Other study ID # TA/0029/2014
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 2013
Est. completion date December 2018

Study information

Verified date March 2019
Source National University Hospital, Singapore
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The objectives are to:

1. derive and validate a panel of miRNAs that are consistently differentially expressed in the plasma of patients with and without sepsis

2. investigate the prognostic and predictive values of the panel of miRNAs to guide treatment

3. investigate the roles of these differentially-expressed circulating miRNAs in immune modulation during sepsis

The methodology involves sampling of blood from controls and subjects in the sepsis continuum at their earliest presentation in the emergency department longitudinally to hospitalization. The investigators will develop panels of miRNAs that are specific to early and late stages of sepsis, and correlate clinical, biochemical and microbiological outcomes with these miRNAs.


Description:

Prospective observational cohort of patients along the entire sepsis continuum in National University Hospital Emergency Department (ED) will be enrolled along with non-infective controls. Whole blood samples will be separated immediately into plasma and serum for storage at the Tissue Repository. Those who are subsequently admitted to the general ward, high dependency (HD) or intensive care unit (ICU) will have their 2nd and 3rd samples obtained at 24-48 hours and 48-72 hours respectively. The 2nd and 3rd samples will be used as prognostic markers (Objective #2). Patients who are discharged directly from the ED will be tracked for any clinical recurrence of their disease within 28 days to ensure the diagnostic accuracy of the first sample of biomarkers that are extracted.

Samples will be batch-processed via the circulating miRNA profiling workflow comprising of the pre-analytics, analytics, and data processing and analysis phases. This qPCR-based miRNA profiling has much smaller feature to sample ratio thus allowing a global sequential forward selection to optimally combine a host of features with complementary prediction strengths to form the biomarker panel which has the least number of components and the maximized classification power (ROC AUC). Panel robustness measurement using computational generated noises and validation with a larger set of blinded samples will be performed.

The final objective will be assessed by measuring the concentrations of secreted cytokines, chemokines and reactive oxygen species after synthesis and transfection the newly-derived miRNA panel into monocytes and monocytic cell lines.


Recruitment information / eligibility

Status Completed
Enrollment 450
Est. completion date December 2018
Est. primary completion date December 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years and older
Eligibility Inclusion criteria for controls:

- Adults 21 years and above

- Has condition unrelated to any infective cause

Exclusion criteria for controls:

- Underlying chronic inflammatory condition (e.g. inflammatory bowel disease)

- Underlying autoimmune disease (e.g. rheumatoid arthritis, systemic lupus erythematosus)

- Pre-existent immunological disorder

Inclusion criteria for subjects:

- Adults 21 years and above

- Clinical/radiological suspicion or confirmation of infection

Exclusion criteria for subjects:

- Age below 21 years

- Prisoners

- Known pregnancy

- Do-not-attempt resuscitation status

- Requirement for immediate surgery

- Active chemotherapy

- Hematological malignancy

- Treating physician deems aggressive care unsuitable

- Unable to provide informed consent or comply with study requirements

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Singapore National University Hospital Singapore

Sponsors (4)

Lead Sponsor Collaborator
National University Hospital, Singapore A*Star, MiRXES Pte Ltd, National University, Singapore

Country where clinical trial is conducted

Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fold changes of miRNA expression Fold changes of differentially-expressed miRNA in log2 scale in comparison to the severity of sepsis (control vs. sepsis vs. septic shock) and adjudicated requirement for hospitalization (yes vs. no) 3 years
Secondary MiRNA panel test performance metrics Sensitivity, specificity and likelihood ratios of capability of miRNA panel to distinguish different severity of sepsis (i.e. requirement for inpatient management) and against standard clinical parameters, C-reactive protein, procalcitonin, and inflammatory cytokines (interleukin-6, interleukin-8). 3 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3